June 25, 2019
Rose
The deal would give AbbVie a potent source of popular treatments as it faces the loss of patent protection for its best-selling drug, Humira.
from Health https://nyti.ms/2X3S9YM
June 25, 2019
Rose
Health, Health - The New York Times
No comments
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment